During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical evidence inform subsequent-line treatment selection for metastatic clear cell renal cell carcinoma.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
The FDA accepted an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2– advanced breast cancer based on the phase 3 VIKTORIA-1 trial, with a PDUFA date of June 25, 2027.
The FDA grants orphan drug designation to TRX-E-002-1, an investigational small-molecule benzopyran, for the treatment of acute myeloid leukemia (AML).
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.